Hims & Hers Health, Inc. - HIMS STOCK NEWS

Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Mike Chi as its first Chief Growth Officer, focusing on growth across its telehealth platform. Under Chi's leadership, the company aims to expand services, particularly in women’s health and mental health, building on a revenue increase of 80% in 2020 and strong Q1 and Q2 results, with year-over-year growth rates of 74% and 69%, respectively. The company also acquired Apostrophe and Honest Health to support growth in dermatology and UK markets.

Hims & Hers Health, Inc. reported Q2 2021 revenue of $60.7 million, a 69% increase year-over-year. The net loss widened to $(9.2) million compared to $(1.0) million a year earlier, despite a gross margin improvement to 78%. Subscriptions rose to 453,000, with 786,000 net orders recorded. The company's acquisitions of Apostrophe and Honest Health are anticipated to accelerate growth in new markets. For Q3 2021, revenue guidance is set at $69-$71 million, with Adjusted EBITDA forecasted at $(9)-(11) million for the quarter and $(35)-(40) million for the full year.

Hims & Hers Health, Inc. (NYSE: HIMS) will release its fiscal Q2 financial results on August 11, 2021, after market close, followed by a conference call at 5:00 p.m. E.T. Investors can access the call by dialing (833) 900-2256 for U.S. participants or (236) 714-2727 internationally, using conference ID # 9972259. A live audio webcast will also be available, with a replay shortly after the call. Hims & Hers offers a telehealth platform connecting consumers with licensed healthcare professionals across various medical fields, providing accessible care across all 50 states.

Hims & Hers Health, Inc. (NYSE: HIMS) announced the redemption of all outstanding warrants to purchase Class A common stock. The warrants will be redeemed at $0.10 each if the stock price is at least $10.00 on the trading day before redemption. A notice has been sent to warrant holders, and trading of public warrants will halt on August 6, 2021. Holders can exercise their warrants until 5:00 p.m. on August 9, 2021, either by cash payment of $11.50 or on a cashless basis, which equates to receiving shares based on market value. Unexercised warrants will be void after the redemption date.

Hims & Hers Health, Inc. (NYSE: HIMS) has launched two new product bundles in response to increasing consumer demand for sexual health products. Recognizing that nearly half of consumers engage in more sexual experimentation post-pandemic, the company unveiled the Pleasure Essentials Kit ($119) and the Ultimate ‘O’ Kit ($299). Each kit combines popular products like condoms, lubricants, and vibrators to enhance intimate experiences. Hims & Hers also offers ongoing access to sexual health treatments, including birth control and erectile dysfunction solutions, reinforcing its commitment to accessible health care.

Hims & Hers Health, Inc. (NYSE: HIMS) has finalized its acquisition of Apostrophe, a teledermatology specialist. This strategic move aims to enhance the company's telehealth offerings, providing advanced, personalized dermatology treatments to consumers. The acquisition will strengthen Hims & Hers' dermatology business, with Apostrophe's team and its CEO, Ben Holber, joining Hims & Hers to lead this segment. The financial terms of the deal were not disclosed, but it reflects the company’s commitment to expand its healthcare services.

Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with Urban Outfitters, Inc. (NASDAQ: URBN) to offer personalized health and wellness solutions on urbanoutfitters.com. This collaboration will begin with select Hims products, expanding to include products from the Hers line, addressing skin care, hair loss, sexual health, and supplements. Melissa Baird, COO of Hims & Hers, emphasized the importance of consumer access to quality health products, while Jena Tracey from Urban Outfitters highlighted the synergy between their customer base and the personalized offerings of Hims & Hers.

Hims & Hers Health, NYSE: HIMS, has announced plans to acquire Apostrophe, a teledermatology specialist, enhancing its focus on personalized dermatology services. This strategic move aims to boost Hims & Hers' ability to deliver tailored treatment plans and expand its market presence, particularly among GenZ and Millennial consumers. Apostrophe's established clinical platform and licensed pharmacy in 29 states will facilitate faster, scalable delivery of dermatology treatments. The acquisition is anticipated to close in Q3 2023, with Apostrophe's CEO expected to lead the dermatology division.

Hims & Hers Health (NYSE: HIMS) has launched Minoxidil 5% Foam for both men and women, enhancing its hair regrowth product line. This FDA-approved treatment is clinically-proven to regrow hair in 3 to 6 months and works by increasing blood flow to hair follicles, activating hair growth, and extending the growth phase. The addition of this foam option responds to customer demand for convenient hair loss solutions. Global superstar Jennifer Lopez endorses this launch, emphasizing the importance of personalized self-care.